Evidence map›Paper›PMID 39661165›Full record

ArticleCancer chemotherapy and pharmacology2024

Sulforaphane inhibits multiple myeloma cell-induced osteoclast differentiation and macrophage proliferation by elevating ferroportin1.

Weichu Sun, Jingqi Sun, Wei Hu, Cong Luo, Zhongwei Lu, Fen He, Hongyan Zhao, Xi Zeng, Deliang Cao, Junjun Li and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Weichu SunDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jingqi SunHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Wei HuHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Cong LuoDepartment of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zhongwei LuDepartment of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Fen HeHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Hongyan ZhaoHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Xi ZengHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Deliang CaoHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Junjun LiDepartment of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Chang ZhangDepartment of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. anniezhc@163.com.
Jiliang XiaHunan Engineering Research Center for Early Diagnosis and Treatment of Liver Cancer, Hengyang Medical School, University of South China, Hengyang, Hunan, China. jiliang-xia@usc.edu.cn.

Funding

Hunan Provincial Innovation Foundation for Postgraduates CX20220975Innovation Platform Open Fund Project of Department of Education of Hunan Province 20K110National College Student Innovation and Entrepreneurship Training Program 210XCX536, 220XCX079, 220XCX254, 220XCX486Natural Science Foundation of Hunan Province 2023JJ10036Natural Science Foundation of Hunan Province 2023JJ60365PhD Scientific Research Start-up Fund of the University of South China 200XQD075Scientific Research Project of Hunan Department of Education 22B0452
6 · The paper itself

Abstract

purposeOsteolysis is a common complication in patients with multiple myeloma (MM). Our previous studies have demonstrated that MM cells can promote osteoclast differentiation of macrophages. In this study, we explored the effect of sulforaphane (SFN), a natural NRF2 activator found in broccoli, on MM cell-induced osteoclast differentiation.

methodsConditional medium (CM) derived from MM cells was used to induce osteoclast differentiation, and TRAP staining was performed to examine osteoclast. Gene expression was detected by western blotting or real-time PCR. Cell counting and EdU staining were performed to test macrophage proliferation.

resultsWe showed that the CM of MM cells downregulated the expression of ferroportin1 (Fpn1), the only known iron exporter in vertebrate cells, thereby increasing cellular iron levels in murine macrophage cells RAW264.7. Deferoxamine (DFO), an iron chelator, effectively blocked MM cell CM-induced osteoclast differentiation and macrophage proliferation, suggesting that iron overload played a key role in these cellular events. Subsequent mechanistic investigations revealed that MM cell CM induced osteoclast differentiation and macrophage proliferation by activating the JNK/AP-1/NFATC1 pathway and PI3K/AKT pathway. SFN was found to increase Fpn1 expression, leading to decreased cellular iron levels in RAW264.7 cells activated by MM cell CM. Importantly, the osteoclast differentiation and macrophage proliferation induced by MM cell CM were significantly inhibited by SFN.

conclusionAltogether, our findings indicated that SFN inhibits MM cell-induced osteoclast differentiation and macrophage proliferation by elevating FPN1 levels. SFN could be a promising therapeutic strategy for MM-associated osteolysis.

Indexed as

Cation Transport ProteinsCell DifferentiationCell ProliferationIsothiocyanatesMacrophagesMultiple MyelomaOsteoclastsSulfoxidesAnimalsCell Line, TumorFerroportinHumansMiceRAW 264.7 CellsCation Transport ProteinsFerroportinIsothiocyanatessulforaphaneSulfoxidesFerroportin1MacrophageMultiple myelomaNRF2OsteoclastSulforaphane

Identifiers

PMID39661165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.